A Randomized, Observer-masked Study of the Safety, Tolerability and Pharmacodynamics of Sequential Ascending 28-Day Repeated Topical Doses of SAR366234 Versus Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension
Phase of Trial: Phase I
Latest Information Update: 29 Apr 2016
At a glance
- Drugs SAR 366234 (Primary) ; Latanoprost
- Indications Open-angle glaucoma
- Focus Adverse reactions
- Sponsors Sanofi
- 26 Apr 2016 Status changed from active, no longer recruiting to completed.
- 13 Apr 2016 Planned End Date changed from 1 Apr 2016 to 1 May 2016.
- 13 Apr 2016 Planned primary completion date changed from 1 Apr 2016 to 1 May 2016.